SPHRY Stock - Starpharma Holdings Limited
Unlock GoAI Insights for SPHRY
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $5.85M | $8.29M | $4.34M | $5.16M | $3.49M |
| Gross Profit | $-3,729,000 | $7.66M | $1.22M | $1.91M | $539,500 |
| Gross Margin | -63.7% | 92.4% | 28.1% | 36.9% | 15.5% |
| Operating Income | $-22,070,000 | $-10,747,000 | $-34,508,000 | $-35,095,000 | $-42,055,000 |
| Net Income | $-9,990,000 | $-8,165,000 | $-15,638,000 | $-16,154,000 | $-19,732,000 |
| Net Margin | -170.8% | -98.5% | -360.1% | -312.9% | -565.9% |
| EPS | $-0.24 | $-0.20 | $-0.38 | $-0.40 | $-0.50 |
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, the company develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase II clinical trial, and DEP irinotecan that is in phase II clinical trials for the treatment of cancer; oncology programs, such as DEP radiopharmaceuticals, DEP HER-2 ADC, and DEP gemcitabine; DEP non-oncology candidates; and DEP AZD0466, which is in Phase I/II clinical trials to treat haematological tumours. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
Visit WebsiteEarnings History & Surprises
SPHRYEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 24, 2026 | — | — | — | — |
Q1 2025 | Feb 26, 2025 | — | — | — | — |
Q4 2024 | Oct 30, 2024 | — | $-0.01 | — | — |
Q2 2024 | May 22, 2024 | — | $-0.00 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.01 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.01 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.01 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.02 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.02 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.02 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-0.02 | — | — |
Q4 2019 | Dec 31, 2019 | — | $-0.01 | — | — |
Q2 2019 | Jun 30, 2019 | — | $-0.01 | — | — |
Q4 2018 | Dec 31, 2018 | — | $-0.01 | — | — |
Q2 2018 | Jun 30, 2018 | — | $-0.01 | — | — |
Q4 2017 | Dec 31, 2017 | — | $-0.01 | — | — |
Q2 2017 | Jun 30, 2017 | — | $-0.01 | — | — |
Q4 2016 | Dec 31, 2016 | — | $-0.02 | — | — |
Q2 2016 | Jun 30, 2016 | — | $-0.51 | — | — |
Q4 2015 | Dec 31, 2015 | — | $-0.02 | — | — |
Latest News
Frequently Asked Questions about SPHRY
What is SPHRY's current stock price?
What is the analyst price target for SPHRY?
What sector is Starpharma Holdings Limited in?
What is SPHRY's market cap?
Does SPHRY pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to SPHRY for comparison